TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18817530

Group type: EXPERIMENTAL
Intervention: Minimized immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolerance application
Number of subjects: 0
Study: 17188782

Group type: EXPERIMENTAL
Intervention: More-aerated snack (0.45 kcal/ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Less-aerated snack (1.00 kcal/ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both snacks served in a bowl and opaque bag
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both snacks
Number of subjects: 28
Study: 15497055

Group type: EXPERIMENTAL
Intervention: HIV prevention workshop
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Condom distribution program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 320
Study: 11740736

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 148
Study: 9249617

Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 50 mg/70 Kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 100 mg/70 Kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS) 200 mg/70 Kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Historical control (untreated)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Curdlan sulfate (CRDS)
Number of subjects: 21
Study: 8325044

Group type: EXPERIMENTAL
Intervention: Etodolac (400 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Diclofenac (150 mg/day)
Number of subjects: 108
Study: 3527706

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oxaprotiline (OT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 59
Study: 31289053

Group type: EXPERIMENTAL
Intervention: On-site sexual health and relationships services
Number of subjects: 2105

Group type: EXPERIMENTAL
Intervention: Staff safeguarding training about sexual health and relationships
Number of subjects: 2105

Group type: EXPERIMENTAL
Intervention: Sex and relationships education
Number of subjects: 2105

Group type: EXPERIMENTAL
Intervention: Student-led sexual health action groups
Number of subjects: 2105
Study: 27819445

Group type: EXPERIMENTAL
Intervention: 3-day brief mindfulness training incorporating instruction in both attention monitoring and acceptance
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mindfulness training incorporating attention monitoring instruction only
Number of subjects: 147

Group type: COMPARATOR
Intervention: Relaxation training condition
Number of subjects: 147

Group type: COMPARATOR
Intervention: Active reading-control condition
Number of subjects: 147
Study: 25733652

Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: DHA/EPA plus placebo
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Iron plus DHA/EPA
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 321
Study: 23929243

Group type: EXPERIMENTAL
Intervention: Biological therapy (TNF-α inhibitors)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy program conducted twice a week for 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy program
Number of subjects: 75
Study: 21745254

Group type: EXPERIMENTAL
Intervention: BoNTA-ABO (50 to 80 U)
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: BoNTA-ABO
Number of subjects: 1740
Study: 19574236

Group type: EXPERIMENTAL
Intervention: Gentamicin pretreatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 41
Study: 17049140

Group type: EXPERIMENTAL
Intervention: Store-and-forward (SF) teledermatology
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional hospital outpatient consultation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Digital photography with and without dermoscopy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 208
Study: 15318955

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FPANS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo nasal spray (PNS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Topical steroids (FPANS)
Number of subjects: 101
Study: 11166493

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9476694

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8176575

Group type: EXPERIMENTAL
Intervention: Turbuhaler dry powder inhaler
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metered-dose inhaler with spacer (Nebuhaler)
Number of subjects: 10
Study: 2438500

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40
Study: 30482701

Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparin (4 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study: 28012280

Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Casein (60 g/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Milk fat high in MC-SFA (63 g/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Milk fat low in MC-SFA (63 g/day)
Number of subjects: 63
Study: 26296511

Group type: EXPERIMENTAL
Intervention: Perampanel (up titrated from 2 to 8 mg/d, or highest tolerated dose)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 23206874

Group type: EXPERIMENTAL
Intervention: Left-hand action effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right-hand action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associative learning for left-hand effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Associative learning for right-hand effects
Number of subjects: 0
Study: 21251654

Group type: EXPERIMENTAL
Intervention: Voluntary counseling and rapid testing (VCT) during labor
Number of subjects: 343

Group type: COMPARATOR
Intervention: Voluntary counseling and rapid testing (VCT) after delivery
Number of subjects: 343
Study: 18433534

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) during CPB
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (no MUF)
Number of subjects: 261
Study: 17067973

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 29
Study: 14661567

Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg bolus injection 3 minutes before propofol injection, followed by continuous infusion at 6 mg.h‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol alone (Group C)
Number of subjects: 120
Study: 10617942

Group type: EXPERIMENTAL
Intervention: Cheek cell phospholipids from infants fed formulas with varying DHA and arachidonic acid intakes
Number of subjects: 31
Study: 8720807

Group type: EXPERIMENTAL
Intervention: Furosemide suppositories
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide sodium suppositories
Number of subjects: 8
Study: 2179481

Group type: EXPERIMENTAL
Intervention: Schedule A (THP at 6 hours, then cisplatin from 16 to 20 hours)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Schedule B (THP at 18 hours, then cisplatin from 4 to 8 hours)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 31

Group type: COMPARATOR
Intervention: Schedule B
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study: 7427858

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR), 60 mg/M2 I.V. q three weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), 40 mg/M2 I.V. q one week
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 500 mg/m2 I.V. x 5 days q five weeks
Number of subjects: 72
Study: 31256606

Group type: EXPERIMENTAL
Intervention: Palliative care intervention for family members in ICUs
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Better family relationship at baseline
Number of subjects: 380
Study: 27974712

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ledipasvir (LDV) therapy
Number of subjects: 147
Study: 26466473

Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nail (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Locking compression plate (Group B)
Number of subjects: 72
Study: 23438509

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22123897

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum positivity
Number of subjects: 224
Study: 20337221

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 94
Study: 17030169

Group type: EXPERIMENTAL
Intervention: VX-950 450 mg every 8 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: VX-950 750 mg every 8 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: VX-950 1250 mg every 12 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: VX-950 (all doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12771500

Group type: EXPERIMENTAL
Intervention: Black Copper Cement (BCC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Glass Ionomer Cement (GIC)
Number of subjects: 45
Study: 10672977

Group type: EXPERIMENTAL
Intervention: labetalol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: labetalol 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 9146587

Group type: EXPERIMENTAL
Intervention: Intravesical Tice strain BCG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7962893

Group type: EXPERIMENTAL
Intervention: Bibliotherapy (BT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group therapy (GT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 36
Study: 2888813

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flucloxacillin (1 mg l-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tobramycin (2 mg l-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 12
Study: 29188336

Group type: EXPERIMENTAL
Intervention: Acute ACLR (within 8 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Delayed ACLR (6-10 weeks)
Number of subjects: 70
Study: 28090594

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 24943105

Group type: EXPERIMENTAL
Intervention: PEG 4000 (8 g per day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Lactulose (3.3 g per day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PEG 4000
Number of subjects: 88

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 21741230

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20828645

Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg bid
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ranolazine 1500 mg bid
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 19075481

Group type: EXPERIMENTAL
Intervention: First day discharge (group B, n = 37)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard hospital stay (group A, n = 19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ejection fraction after 30 days (group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ejection fraction after 30 days (group B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 56
Study: 15729252

Group type: EXPERIMENTAL
Intervention: Video headset
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional monitor
Number of subjects: 96
Study: 12847356

Group type: EXPERIMENTAL
Intervention: Pathway of controlled rehabilitation with early ambulation and diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional postoperative care
Number of subjects: 64
Study: 10389680

Group type: EXPERIMENTAL
Intervention: Tramadol (840 mg, range: 80-1920 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Morphine (238 mg, range: 20-1125 mg)
Number of subjects: 25
Study: 8657100

Group type: EXPERIMENTAL
Intervention: Bright Light (BL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dim Light (DL)
Number of subjects: 8
Study: 1357451

Group type: EXPERIMENTAL
Intervention: Clodronate 2.4 g daily for 24 months
Number of subjects: 350
Study: 3890986

Group type: EXPERIMENTAL
Intervention: PPSB (prothrombin complex preparation)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (without PPSB)
Number of subjects: 268
Study: 30348142

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education via a smartphone app (unidirectional text messages, evidence and psychological theory based, regarding dietary habits, physical activity, hypoglycaemia, and glucose variability) for 6 or 9 months, frequency chosen by patients (2-6 times per week).
Number of subjects: 228

Group type: COMPARATOR
Intervention: Care-as-usual (control group).
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education via a smartphone app.
Number of subjects: 228
Study: 26394360

Group type: EXPERIMENTAL
Intervention: Oral iron treatment (80 mg/day for 4 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 24868583

Group type: EXPERIMENTAL
Intervention: 0.12% topical unoprostone twice daily in a randomly selected eye
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control RP patients
Number of subjects: 40
Study: 21993491

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1021
Study: 20178625

Group type: EXPERIMENTAL
Intervention: Low sodium vegetable juice (8 or 16 fluid ounces daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Diet counseling only (control group)
Number of subjects: 81
Study: 18430966

Group type: EXPERIMENTAL
Intervention: Carbohydrate with protein (CHO + PRO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 10
Study: 16223056

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Form 90 AIR/ED
Number of subjects: 0
Study: 12586793

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2))
Number of subjects: 739

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m(2)/24 h)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and paclitaxel (AT, 50 mg/m(2) and 150 mg/m(2)/24 h, plus granulocyte colony‐stimulating factor 5 mg/kg)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 739

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Combination of doxorubicin and paclitaxel (AT)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Doxorubicin to Paclitaxel crossover
Number of subjects: 739

Group type: COMPARATOR
Intervention: Paclitaxel to Doxorubicin crossover
Number of subjects: 739
Study: 10028207

Group type: EXPERIMENTAL
Intervention: Timeline Follow‐Back (TLFB)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Weekly calendar reports
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self‐report measures
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self‐report measures over time
Number of subjects: 65
Study: 8694157

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg added to prilocaine in a standard Bier's block (group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Standard Bier's block with tenoxicam given intravenously into the contralateral arm (group 3)
Number of subjects: 45
Study: 1997063

Group type: EXPERIMENTAL
Intervention: Extradural analgesia with local anaesthetics for 3 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 48
Study: 7061773

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) received a mean cumulative dose of 3440 microgram cat allergen 1 (cat 1) and 10,660 microgram cat albumin (alb).
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermediate-dose group (IDG) received 70 microgram cat 1 and 217 microgram alb.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) received 0.930 microgram cat 1 and 2.86 microgram alb.
Number of subjects: 16
Study: 31454771

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29947322

Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study: 27247174

Group type: EXPERIMENTAL
Intervention: Life Goals‐Collaborative Care (LG‐CC)
Number of subjects: 219
Study: 24664108

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (intelligence test HAWIK‐IV)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise (running at 65‐75% of maximum heart rate for 15 minutes)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (regular school lesson)
Number of subjects: 62
Study: 22281403

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy in patients with VRS
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no chest physiotherapy) in patients with VRS
Number of subjects: 236
Study: 20932401

Group type: EXPERIMENTAL
Intervention: Energy drinks (various types)
Number of subjects: 9
Study: 18803940

Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 41
Study: 15860766

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12165641

Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil-based chemotherapy
Number of subjects: 3380
Study: 10434212

Group type: EXPERIMENTAL
Intervention: Intraoperative analgesia
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Regional analgesia (subset of 185 patients with genitourinary procedures)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Poor pain relief
Number of subjects: 471
Study: 7887699

Group type: EXPERIMENTAL
Intervention: Kety-Schmidt technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Xenon-133 clearance
Number of subjects: 20
Study: 2624617

Group type: EXPERIMENTAL
Intervention: Low-potassium diet (10 mmol per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal-potassium diet (90 mmol per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline infusion in potassium-depleted subjects
Number of subjects: 10
Study: 31559589

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (300,000 IU for deficiency, 150,000 IU for insufficiency) administered orally 48 hours before CABG surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 116
Study: 29779316

Group type: EXPERIMENTAL
Intervention: Artificial kidney seeper group (inserted by a ureteral catheter)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Non-artificial kidney seeper group (underwent PCNL directly)
Number of subjects: 287
Study: 27935423

Group type: EXPERIMENTAL
Intervention: Unilateral balance training (dominant leg) over 4 weeks (4×/week)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Unilateral balance training (dominant leg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study: 25172701

Group type: EXPERIMENTAL
Intervention: Tomato juice with 10% refined olive oil (750g/70kg BW)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tomato juice without oil (750g/70kg BW)
Number of subjects: 11
Study: 23772760

Group type: EXPERIMENTAL
Intervention: Spanish version of the Short Inventory of Problems (SIP-RS)
Number of subjects: 405
Study: 20885426

Group type: EXPERIMENTAL
Intervention: IOPen rebound tonometer
Number of subjects: 198

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 198
Study: 18781066

Group type: EXPERIMENTAL
Intervention: 2% starch gel-like solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10% sucrose solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2% starch and 10% sucrose solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2% starch solution followed by 10% sucrose solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Starch (2%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sucrose (10%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Starch + Sucrose
Number of subjects: 11
Study: 16781376

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study: 14981969

Group type: EXPERIMENTAL
Intervention: Levovist power Doppler ultrasound (Levovist US)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Spiral computed tomography (spiral CT)
Number of subjects: 46